Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Down 44.2% in June

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the recipient of a large drop in short interest during the month of June. As of June 15th, there was short interest totaling 9,143 shares, a drop of 44.2% from the May 31st total of 16,388 shares. Based on an average daily volume of 19,697 shares, the short-interest ratio is currently 0.5 days. Currently, 0.4% of the company’s shares are short sold.

Xenetic Biosciences Trading Down 0.3%

XBIO traded down $0.01 during trading hours on Wednesday, hitting $2.90. 51,208 shares of the company’s stock were exchanged, compared to its average volume of 18,469. The firm has a market cap of $6.64 million, a P/E ratio of -2.37 and a beta of 2.19. The firm has a 50 day moving average of $3.06 and a 200 day moving average of $2.71. Xenetic Biosciences has a 12-month low of $1.90 and a 12-month high of $13.93.

Xenetic Biosciences (NASDAQ:XBIO) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. Xenetic Biosciences had a negative net margin of 70.03% and a negative return on equity of 39.28%. The company had revenue of $0.81 million during the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Institutional Investors Weigh In On Xenetic Biosciences

An institutional investor recently raised its stake in Xenetic Biosciences stock. Renaissance Technologies LLC boosted its stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 516.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 178,509 shares of the company’s stock after acquiring an additional 149,559 shares during the period. Renaissance Technologies LLC owned about 7.80% of Xenetic Biosciences worth $387,000 as of its most recent SEC filing. Institutional investors own 15.12% of the company’s stock.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.